Novartis is to deepen its presence in radiopharmaceuticals with the acquisition of Mariana Oncology, a preclinical biotechnology company based in the US. Announced on 2 May, the deal involves an upfront cash payment of $1 billion and potential outlays of up to $750 million depending on the achievement of certain undisclosed milestones.
